Quarterly ResultAug 12, 2026, 04:18 PM
Allogene Q2 Net Loss $42.7M; Cema-Cel Gets RMAT/Fast Track
AI Summary
Allogene Therapeutics reported a Q2 2026 net loss of $42.7 million, or $0.13 per share. The company ended the quarter with $423.6 million in cash, cash equivalents, and investments, projecting a cash runway into 2029. Key clinical updates include FDA granting RMAT and Fast Track designations for Cema-Cel in 1L LBCL following a positive interim futility analysis, with accelerated site activation for the ALPHA3 trial. Enrollment for the ALPHA3 trial is expected to complete by year-end 2027, and a clinical data update for the ALLO-329 autoimmune trial is anticipated in Q4 2026.
Key Highlights
- FDA granted RMAT and Fast Track designations for Cema-Cel in 1L LBCL.
- ALPHA3 trial site activation accelerated, with 100 sites expected by year-end 2026.
- Q2 2026 net loss was $42.7 million, or $0.13 per share.
- Ended Q2 2026 with $423.6 million in cash, cash equivalents, and investments.
- Projected cash runway extends into 2029.
- Research and development expenses were $30.7 million for Q2 2026.
- General and administrative expenses were $20.8 million for Q2 2026.
- ALLO-329 clinical data update expected in Q4 2026.
Price Impact
More from ALLO